MiMedx Group Rises While Domestic Stocks Tally Mild Losses

Domestic stocks retreated today, led by a tech-sector drop and the NASDAQ shaving off -0.38%. Meanwhile, MiMedx Group (OTC: MDXG) rose 16% in over-the-counter trading. The recent volatility of domestic stocks has been attributed to the global effects of the European market, but over-the-counter trading is typically not affected by macro concerns. While Europe stays in a wait-and-see mode regarding Greek election results, we are left in an information vacuum for one more month.

MiMedx Group’s stock shares have been providing consistent performance in over the counter market. Including its respectable rally today, the stock value has gained 28% since January 1, 2012. MiMedx Group hit a bottom low on April 17, but has continued to climb until today’s full recovery.

MiMedx Group is a name in the biomaterial products industry. The company develops, manufactures and markets various biomaterial products that are meant for diverse concerns including repair of soft tissue, tendons, cartilage and ligaments. MiMedx works with tissue technologies that are acquired from the amniotic membrane of humans.

In January 2011, MiMedx Group successfully acquired all equity interests from Surgical Biologics. The aggregate totals $16.4 million including stock, cash plus assumed debt. This was a strategic acquisition. While Mimedx already owned market leading know-how technology in amnion tissue, the new acquisition brought a global distribution network which was positioned for exploiting other market opportunities.

On April 30, 2012, the company announced its selections for Allen & Caron in different cities including New York, London and Irvine, California. The purpose of this business agreement was to develop healthy investor relations as well as better business communications. Allen & Caron will now be responsible for establishing a specific outreach program in order to raise investment profits and the growth of business media. Allen & Caron has a reputation for implementing planned objectives and accomplishing dynamic growth strategies.

ROA (Return on Assets) for MiMedx Group returns 17.74 %, a figure close to the current health care average of 17.61 %. This ROA is usually obtained by calculating a company’s revenue over its general assets. In the future, MiMedx will need to maintain a similar ROA to achieve considerable revenue over its total assets.

Amid all the troubles of the social media IPO market and the U.S. economy, MiMedx Group rose 16% today and continues to provide solid performance in the over-the-counter market. The company’s marketing strategies have been contributing to its financial performance and stock performance. In today’s market full of volatility, investors are more convinced than ever to avoid risky businesses and go for the ones that are less of a gamble.

For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.

Published by Fiona Gibson

Fiona is a finance graduate and an expert in analyzing market trends.